# A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

> **NCT07672236** · PHASE3 · RECRUITING · sponsor: **OncoZenge AB** · enrollment: 150 (estimated)

## Conditions studied

- Head & Neck Cancer
- Oral Mucositis

## Interventions

- **DRUG:** BupiZenge 25 mg
- **DRUG:** Lidocaine viscous 2%

## Key facts

- **NCT ID:** NCT07672236
- **Lead sponsor:** OncoZenge AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2026-12-23
- **Final completion:** 2027-01-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672236, "A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*